Healthbook WCLC Newsroom: Summery of IMpower133

Five year survival in patients with ES-SCLC treated with atezolizumab in IMpower133:
IMbrella A extension study results, presented by Prof. Rafal Dziadziuszko

Published: 31/01/24

You are about to leave Roche4Med website. Links to external web pages are offered for your convenience. Roche Pharmaceuticals (Israel) Ltd. is not responsible for the content displayed on those pages.